InGel Therapeutics
Cambridge, US · Founded 2022 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
MS
Myron SpectorNamed on SEC filing
PC
Pierre Colombe DromelNamed on SEC filing
DS
Deepti SinghNamed on SEC filing
MY
Michael YoungNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$350K disclosed across 1 round · 2022
▶$350KraisedAug 2022 · 4 investors · BiotechnologyRule 506(b)
▶$350KraisedAug 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Myron SpectorDirector
- Pierre Colombe DromelExecutive Officer, Director
- Deepti SinghDirector
- Michael YoungDirector
- Offering amount
- $1M
- Amount sold
- $350K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are InGel Therapeutics's investors?
- InGel Therapeutics's investors include ZAKA VC.
- How much funding has InGel Therapeutics raised?
- InGel Therapeutics has disclosed $350K raised across 1 round.
- Where is InGel Therapeutics headquartered?
- InGel Therapeutics is headquartered in Cambridge, US.